DMAC: DiaMedica Therapeutics Inc. Company Aggregate Debts

DiaMedica Therapeutics (DMAC) is developing a therapy to support excretory system functions. Geopolitical conflicts are blocking global research and disrupting biomaterial supplies, which is stalling tests. This chart of the market debt valuation on GURU.Markets is fixed at 0.00. The absence of profitable assets and zero cash flow make the company dependent on external financing during the development stage.

This metric reflects the sensitivity of the capital structure to fluctuations in the market value of assets. The indicator compares total borrowings with current capitalization, revealing the level of financial leverage in real time. For DiaMedica Therapeutics (DMAC), which lacks revenue and is awaiting Phase 2 results, this is a critical marker of solvency. An increase in total debt signals a risk of liquidity shortages. Analyzing this total debt allows for an assessment of the business's resilience to macro shocks.